293 related articles for article (PubMed ID: 22889147)
21. Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient.
Boyd SD; Maldarelli F; Sereti I; Ouedraogo GL; Rehm CA; Boltz V; Shoemaker D; Pau AK
Antivir Ther; 2011; 16(2):257-61. PubMed ID: 21447876
[TBL] [Abstract][Full Text] [Related]
22. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM;
AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288
[TBL] [Abstract][Full Text] [Related]
23. Raltegravir-based regimens are effective in HIV-1 group O-infected patients.
Depatureaux A; Leoz M; Le Moal G; Pathé JP; Pavie J; Batisse D; Daneluzzi V; Genet P; Gerard L; Lascaux-Cametz AS; Lambolez T; Chennebault JM; Plantier JC
J Acquir Immune Defic Syndr; 2012 Sep; 61(1):e1-3. PubMed ID: 22918125
[No Abstract] [Full Text] [Related]
24. Anti-HIV agents. Merck integrase inhibitor.
TreatmentUpdate; 2006; 18(4):3-4. PubMed ID: 17205652
[No Abstract] [Full Text] [Related]
25. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
Raffi F; Rachlis A; Stellbrink HJ; Hardy WD; Torti C; Orkin C; Bloch M; Podzamczer D; Pokrovsky V; Pulido F; Almond S; Margolis D; Brennan C; Min S;
Lancet; 2013 Mar; 381(9868):735-43. PubMed ID: 23306000
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression.
Santos JR; Llibre JM; Ferrer E; Domingo P; Imaz A; Moltó J; Martin-Iguacel R; Caum C; Podzamczer D; Clotet B
HIV Clin Trials; 2009; 10(6):432-8. PubMed ID: 20133273
[TBL] [Abstract][Full Text] [Related]
27. Darunavir-etravirine-raltegravir as salvage combination therapy in a heavily pretreated HIV-infected patient.
Vento S; Vallone A
AIDS Patient Care STDS; 2008 Nov; 22(11):841-2. PubMed ID: 19025477
[No Abstract] [Full Text] [Related]
28. CROI 2009: a few key presentations on antiretroviral therapy.
Gallant JE
AIDS Read; 2009 Apr; 19(4):129-30, C3. PubMed ID: 19388179
[No Abstract] [Full Text] [Related]
29. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.
Buzón MJ; Massanella M; Llibre JM; Esteve A; Dahl V; Puertas MC; Gatell JM; Domingo P; Paredes R; Sharkey M; Palmer S; Stevenson M; Clotet B; Blanco J; Martinez-Picado J
Nat Med; 2010 Apr; 16(4):460-5. PubMed ID: 20228817
[TBL] [Abstract][Full Text] [Related]
30. [New antiretroviral drug classes in HIV therapy].
Lehmann C; Meuer K; Kümmerle T; Fätkenheuer G
MMW Fortschr Med; 2009 Apr; 151(18):64-6. PubMed ID: 19769081
[No Abstract] [Full Text] [Related]
31. Integrase inhibitors for the treatment of HIV infection.
Pace P; Rowley M
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):471-9. PubMed ID: 18600564
[TBL] [Abstract][Full Text] [Related]
32. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
[TBL] [Abstract][Full Text] [Related]
33. Similar efficacy and tolerability of raltegravir-based antiretroviral therapy in HIV-infected patients, irrespective of age group, burden of comorbidities and concomitant medication: Real-life analysis of the German 'WIP' cohort.
Naumann U; Moll A; Schleehauf D; Lutz T; Schmidt W; Jaeger H; Funke B; Witte V
Int J STD AIDS; 2017 Aug; 28(9):893-901. PubMed ID: 28385065
[TBL] [Abstract][Full Text] [Related]
34. [Raltegravir: the first HIV integrase inhibitor. Introduction].
Gatell JM
Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():1-2. PubMed ID: 19572418
[No Abstract] [Full Text] [Related]
35. Analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and quality of life at 24 weeks.
Sayana S; Prosser P; Ricaurte JC; Sanchez S; Hamwi G; Hershey-Weber J; Chien C; Easley A; Nguyen T; Wilson L; Khanlou H
J Int Assoc Physicians AIDS Care (Chic); 2009; 8(2):85-6. PubMed ID: 19369697
[No Abstract] [Full Text] [Related]
36. [Integrase inhibitor: raltegravir also as first line therapy].
MMW Fortschr Med; 2010 Apr; 152(17):48. PubMed ID: 20509261
[No Abstract] [Full Text] [Related]
37. Raltegravir: an integrase inhibitor for HIV-1.
Evering TH; Markowitz M
Expert Opin Investig Drugs; 2008 Mar; 17(3):413-22. PubMed ID: 18321239
[TBL] [Abstract][Full Text] [Related]
38. Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.
Burger DM
Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1151-60. PubMed ID: 20701552
[TBL] [Abstract][Full Text] [Related]
39. No residual activity of raltegravir after development of 148 complex mutations in vivo.
Khanlou H; Sayana S; Acosta E
J Int Assoc Physicians AIDS Care (Chic); 2008; 7(6):281-2. PubMed ID: 19164138
[No Abstract] [Full Text] [Related]
40. Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents.
Briz V; León-Leal JA; Palladino C; Moreno-Perez D; de Ory SJ; De José MI; González-Tomé MI; Martín CG; Pocheville I; Ramos JT; Leal M; Muñoz-Fernández MÁ
Pediatr Infect Dis J; 2012 Mar; 31(3):273-7. PubMed ID: 22330165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
